{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:50:06Z","timestamp":1792673406922,"version":"4.5.0"},"reference-count":39,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T00:00:00Z","timestamp":1549843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["L2P1367 - L2P1520"],"award-info":[{"award-number":["L2P1367 - L2P1520"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Radio-ligand therapy (RLT) with177Lu-PSMA-617 is a promising option for patients with metastatic castration-resistant prostate-cancer (mCRPC). A prospective phase-II study (EUDRACT\/RSO,2016-002732-32) on mCRPC is ongoing at IRST (Meldola, Italy). A total of 9 patients (median age: 68 y, range: 53\u201385) were enrolled for dosimetry evaluation of parotid glands (PGs), kidneys, red marrow (RM) and whole body (WB). Folic polyglutamate tablets were orally administered as PGs protectors and 500 mL of a 10% mannitol solution was intravenously infused to reduce kidney uptake. The whole body planar image (WBI) and blood samples were acquired at different times post infusion (1 h, 16\u201324 h, 36\u201348 h and 120 h). Dose calculation was performed with MIRD formalism (OLINDA\/EXM software). The median effective half-life was 33.0 h (range: 25.6\u201360.7) for PGs, 31.4 h (12.2\u201380.6) for kidneys, 8.2 h (2.5\u201314.7) for RM and 40.1 h (31.6\u201379.7) for WB. The median doses were 0.48 mGy\/MBq (range: 0.33\u20132.63) for PGs, 0.70 mGy\/MBq (0.26\u20131.07) for kidneys, 0.044 mGy\/MBq (0.023\u20130.067) for RM and 0.04 mGy\/MBq (0.02\u20130.11) for WB. A comparison with previously published dosimetric data was performed and a significant difference was found for PGs while no significant difference was observed for the kidneys. For PGs, the possibility of reducing uptake by administering glutamate tablets during RLT seems feasible while further research is warranted for a more focused evaluation of the reduction in kidney uptake.<\/jats:p>","DOI":"10.3390\/molecules24030621","type":"journal-article","created":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T03:18:20Z","timestamp":1549941500000},"page":"621","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Dosimetry of 177Lu-PSMA-617 after Mannitol Infusion and Glutamate Tablet Administration: Preliminary Results of EUDRACT\/RSO 2016-002732-32 IRST Protocol"],"prefix":"10.3390","volume":"24","author":[{"given":"Anna","family":"Sarnelli","sequence":"first","affiliation":[{"name":"Medical Physics Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1983-3291","authenticated-orcid":false,"given":"Maria Luisa","family":"Belli","sequence":"additional","affiliation":[{"name":"Medical Physics Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5380-6185","authenticated-orcid":false,"given":"Valentina","family":"Di Iorio","sequence":"additional","affiliation":[{"name":"Oncology Pharmacy, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0150-7757","authenticated-orcid":false,"given":"Emilio","family":"Mezzenga","sequence":"additional","affiliation":[{"name":"Medical Physics Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Celli","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Severi","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Tardelli","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Nicolini","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devil","family":"Oboldi","sequence":"additional","affiliation":[{"name":"Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1490-0718","authenticated-orcid":false,"given":"Licia","family":"Uccelli","sequence":"additional","affiliation":[{"name":"Diagnostic Imaging Unit\u2014Morphology, Surgery and Experimental Medicine Department, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5117-804X","authenticated-orcid":false,"given":"Corrado","family":"Cittanti","sequence":"additional","affiliation":[{"name":"Diagnostic Imaging Unit\u2014Morphology, Surgery and Experimental Medicine Department, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Monti","sequence":"additional","affiliation":[{"name":"Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahila","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Physics, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Paganelli","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,2,11]]},"reference":[{"key":"ref_1","first-page":"E359","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","volume":"3","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.eururo.2011.01.025","article-title":"EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing and castration-resistant prostate cancer","volume":"59","author":"Mottet","year":"2011","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nrurol.2014.36","article-title":"Prostate cancer: Treatment sequencing for CRPC\u2014What do we know?","volume":"11","author":"Heidenreich","year":"2014","journal-title":"Nat. Rev. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s00268-005-0544-5","article-title":"Expression of prostate-specific membrane antigen in normal and malignant humantissues","volume":"30","author":"Kinoshita","year":"2006","journal-title":"World J. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","article-title":"PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-Labeled PSMA-617","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/14737159.2016.1243057","article-title":"Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer","volume":"11","author":"Barrio","year":"2016","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","article-title":"177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: Safety and efficacy","volume":"57","author":"Baum","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","article-title":"Dosimetry for 177Lu-DKFZ-PSMA-617: A new radiopharmaceutical for the treatment of metastatic prostate cancer","volume":"43","author":"Delker","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1007\/s00259-015-3125-3","article-title":"Pre-therapeutic dosimetry of normal organs and tissues if 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration resistant prostate cancer","volume":"42","author":"Kabasakal","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13550-018-0408-2","article-title":"Impact of external cooling with icepacks on 68Ga-PSMA uptake in salivary glands","volume":"8","author":"Lam","year":"2018","journal-title":"EJNMMI Res."},{"key":"ref_11","first-page":"617","article-title":"New advances in peptide receptor radionuclide therapy","volume":"43","author":"Krenning","year":"2002","journal-title":"J. Nucl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/ndt\/gfh362","article-title":"Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues","volume":"19","author":"Barone","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00259-003-1117-1","article-title":"86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)\u2014A phase 1 clinical study: Pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion","volume":"30","author":"Jamar","year":"2003","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2967\/jnumed.110.075101","article-title":"Renal toxicity of radiolabeled peptides and antibody fragments: Mechanisms, impact on radionuclide therapy and strategies for prevention","volume":"51","author":"Vegt","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"97S","DOI":"10.2967\/jnumed.115.170167","article-title":"PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: The bad berka experience since 2013","volume":"57","author":"Kulkarni","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.urology.2007.03.025","article-title":"Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms","volume":"70","author":"Baccala","year":"2007","journal-title":"Urology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6678","DOI":"10.1016\/j.bmc.2007.08.006","article-title":"Substrate specificity of prostate-specific membrane antigen","volume":"15","author":"Engle","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s00259-017-3791-4","article-title":"Reduction of 68Ga-PSMA renal uptake with mannitol infusion: Preliminary results","volume":"44","author":"Matteucci","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_19","first-page":"58","article-title":"The evolving Gleason grading system","volume":"28","author":"Chen","year":"2016","journal-title":"Chin. J. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Violet, J.A., and Jackson, P. (2018). Dosimetry of Lu-177 PSMA-617 in metastatic castration-resistant prostate cancer: Correlations between pre-therapeutic imaging and \u201cwhole body\u201d tumor dosimetry with treatment outcomes. J. Nucl. Med.","DOI":"10.2967\/jnumed.118.219352"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2967\/jnumed.117.203539","article-title":"Targeted alpha therapy of mCRPC with 225Actinium-PSMA-617: Swimmer-plot analysis suggests efficacy regarding duration of tumor-control","volume":"59","author":"Kratochwil","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2967\/jnumed.118.207993","article-title":"PSMA-Targeted Radionuclide Therapy and salivary gland toxicity: Why does it matter?","volume":"59","author":"Foletti","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","article-title":"Targeted alpha therapy of mCRPC with 225Actinium-PSMA-617: Dosimetry estimate and empirical dose finding","volume":"58","author":"Kratochwil","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_25","first-page":"83","article-title":"Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0, Tyr3-Octreotide and 177Lu-DOTA0, Tyr3-Octreotate","volume":"46","author":"Valkema","year":"2005","journal-title":"J. Nucl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Nedelcovych, M.T., and Dash, R.P. (2018). JHU-2545 selectively shields salivary glands and kidneys during PSMA-Targeted radiotherapy. bioRxiv, 1\u201336.","DOI":"10.1101\/457085"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_29","first-page":"1","article-title":"Radiometabolic Therapy (RMT) with 177Lu PSMA 617 in advanced castration resistant prostate cancer (CRPC): Efficacy and toxicity evaluation","volume":"1","author":"Paganelli","year":"2017","journal-title":"IRST Protoc."},{"key":"ref_30","first-page":"3","article-title":"Norme di buona preparazione dei radiofarmaci in medicina nucleare","volume":"1","author":"Salvo","year":"2006","journal-title":"AIMN Notiziario di Medicina Nucleare ed Imaging Molecolare"},{"key":"ref_31","first-page":"6423","article-title":"Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5","volume":"50","author":"Lopes","year":"1990","journal-title":"Cancer Res."},{"key":"ref_32","unstructured":"Stabin, M.G. (2008). Foundamentals of Nuclear Medicine Dosimetry, Springer."},{"key":"ref_33","first-page":"37S","article-title":"MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates","volume":"40","author":"Siegel","year":"1999","journal-title":"J. Nucl. Med."},{"key":"ref_34","unstructured":"Snyder, W.S., and Ford, M.R. (2018, January 28). \u201cS\u201d Absorbed Dose Per Unt Cumulate Activity for Selected Radionuclides and Organs. Available online: http:\/\/snmmi.files.cms-plus.com\/docs\/hpra\/MIRD Pamphlet 11.pdf."},{"key":"ref_35","first-page":"11s","article-title":"MIRD Pamphlet No. 17: The dosimetry of nonuniform activity distributions-radionuclide S values at the voxel level","volume":"40","author":"Bolch","year":"1998","journal-title":"J. Nucl. Med."},{"key":"ref_36","first-page":"1023","article-title":"OLINDA\/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine","volume":"46","author":"Stabin","year":"2005","journal-title":"J. Nucl. Med."},{"key":"ref_37","first-page":"149","article-title":"Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes","volume":"41","author":"Stabin","year":"2000","journal-title":"J. Nucl. Med."},{"key":"ref_38","first-page":"689","article-title":"Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations","volume":"34","author":"Sgouros","year":"1993","journal-title":"J. Nucl. Med."},{"key":"ref_39","first-page":"349","article-title":"Calculations in apheresis","volume":"28","author":"Neyrinck","year":"2013","journal-title":"J. Clin. Apher."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/3\/621\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:31:01Z","timestamp":1760185861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/3\/621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,11]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,2]]}},"alternative-id":["molecules24030621"],"URL":"https:\/\/doi.org\/10.3390\/molecules24030621","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,11]]}}}